Saturday 17 October 2026
Export NVST’s income statement to Excel — free account
Envista Holdings Corporation
NVST Healthcare Medical Instruments & Supplies
Envista Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 8.32% from fiscal 2024. In the quarter to June 2026, revenue grew 7.10%, EPS grew 106.3%, free cash flow grew 37.6% and total debt was flat, each against the same quarter a year earlier.
22.90
0.60
−2.55%
Follow NVST
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
44.66 | 60.40 | 77.54 | 226.33 |
+8 more quarters Free account |
P/S ratio |
1.49 | 1.48 | 1.34 | 1.29 | |
P/FCF ratio |
17.13 | 18.87 | 15.80 | 12.86 | |
P/Operating CF |
35.79 | (1,260.04) | 33.77 | 42.99 | |
P/B ratio |
1.39 | 1.35 | 1.17 | 1.10 | |
Price to Tangible BV |
38.96 | 47.96 | 30.17 | 42.45 | |
EV/Sales |
1.64 | 1.65 | 1.47 | 1.45 | |
EV/EBITDA |
10.94 | 11.68 | 10.78 | 11.14 | |
EV/Operating CF |
15.51 | 17.02 | 14.51 | 12.70 | |
EV/FCF |
18.85 | 21.02 | 17.32 | 14.49 | |
Quick Ratio |
1.94 | 1.93 | 1.93 | 1.87 | |
Current Ratio |
2.43 | 2.44 | 2.38 | 2.37 | |
Net Debt/EBITDA |
2.62 | 3.50 | 2.11 | 3.23 | |
Debt/Assets |
25.66% | 25.80% | 25.50% | 25.62% | |
Debt/Equity |
0.47 | 0.47 | 0.47 | 0.47 | |
Asset Turnover |
0.51 | 0.51 | 0.49 | 0.47 | |
Operating CF/Net income |
2.22 | (0.09) | 3.28 | (2.60) | |
Capex/Depreciation |
(0.37) | (0.32) | (0.42) | (0.28) | |
Interest Coverage |
9.23 | 8.45 | 7.12 | 6.39 | |
Research and Development Expense of Revenue |
4.16% | 4.25% | 4.28% | 4.22% | |
Selling, General and Administrative Expense of Revenue |
40.56% | 42.18% | 40.66% | 42.45% | |
Intangible Assets out of Total Assets |
0.53 | 0.54 | 0.53 | 0.53 | |
Share Based Compensation of Revenue |
1.30% | 1.45% | 1.39% | 1.55% | |
Graham Net Nets |
(0.13) | (0.14) | (0.15) | (0.18) | |
Graham Number |
15.88 | 13.33 | 10.79 | 6.14 | |
Earnings Yield |
2.24% | 1.66% | 1.29% | 0.44% | |
Free Cash Flow Yield |
5.84% | 5.30% | 6.33% | 7.78% | |
Revenue per Share |
4.51 | 4.30 | 4.47 | 4.03 | |
Operating CF per Share |
0.74 | (0.02) | 0.64 | 0.47 | |
Capex per Share |
(0.09) | (0.08) | (0.10) | (0.06) | |
Free Cash Flow per Share |
0.65 | (0.10) | 0.55 | 0.41 | |
Cash per Share |
6.95 | 6.61 | 7.21 | 6.83 | |
Shareholders Equity per Share |
19.00 | 18.79 | 18.49 | 18.59 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
19.00 | 18.79 | 18.49 | 18.59 | |
Free Cash Flow |
105.10 | (15.70) | 91.70 | 67.90 | |
Working Capital |
1,150.70 | 1,132.50 | 1,174.00 | 1,126.60 | |
Capital Expenditures |
(14.10) | (12.40) | (16.30) | (10.80) | |
Net Current Asset Value |
(562.80) | (579.40) | (546.10) | (606.00) | |
EV/EBIT |
17.15 | 19.33 | 18.51 | 20.18 | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 | |
Price to Operating Income |
15.59 | 17.35 | 16.88 | 17.91 | |
| Other line items | |||||
Average Receivables |
429.85 | 414.85 | 396.30 | 399.00 | |
Average Payables |
181.00 | 166.75 | 183.10 | 164.05 | |
Average Inventory |
286.40 | 280.80 | 264.55 | 278.20 | |
Average Assets |
5,630.75 | 5,522.20 | 5,514.75 | 5,576.60 | |
Average Common Equity |
3,107.65 | 3,057.80 | 3,020.55 | 3,080.35 |
Columns are period end dates